Corient Private Wealth
SUPN icon

Corient Private Wealth’s Supernus Pharmaceuticals SUPN Stock Holding History

Corient Private Wealth’s Portfolio SUPN Stock Details SUPN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$240K Buy
5,163
+321
+7% +$15.4K ﹤0.01% 2699
2026
Q1 		$250K Buy
4,842
+75
+2% +$3.82K ﹤0.01% 2423
2025
Q4 		$237K Buy
+4,767
New +$232K ﹤0.01% 2333

Other funds holding SUPN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
NAMI
Nomura Asset Management International Philadelphia, Pennsylvania $66.6B AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
SIMG
Stephens Investment Management Group Houston, Texas $9.33B AUM 56.1% 1-Year Est. Return

Corient Private Wealth's SUPN Position: Q2 2026 in Review

Corient Private Wealth increased its Supernus Pharmaceuticals (SUPN) stake by 6.6% in Q2 2026, buying an estimated $15.4K and bringing the position to 5,163 shares worth $240K. The position accounts for ﹤0.01% of the portfolio, ranked #2699.

Corient Private Wealth first reported a position in SUPN in Q4 2025 and has held it in 3 quarters since. The position peaked at $250K in Q1 2026. 334 funds tracked by Wall St. Rank hold SUPN as of Q2 2026.

  • Corient Private Wealth held 5,163 shares of Supernus Pharmaceuticals worth $240K as of Q2 2026.
  • Corient Private Wealth bought 321 Supernus Pharmaceuticals shares in Q2 2026, an estimated $15.4K.
  • Supernus Pharmaceuticals made up ﹤0.01% of Corient Private Wealth's portfolio in Q2 2026, its #2699 holding.
  • Corient Private Wealth first reported a position in Supernus Pharmaceuticals in Q4 2025 and has held it in 3 quarters since.
  • Corient Private Wealth's Supernus Pharmaceuticals position peaked at $250K in Q1 2026.
  • 334 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q2 2026.

Based on Corient Private Wealth's 13F filing for Q2 2026, filed 12 Aug 2026.